Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant
2010
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
2010 StandoutScience
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
2009
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
A tyrosine-reactive irreversible inhibitor for glutathione S -transferase Pi (GSTP1)
2016
Treatment of therapy-induced preleukemic syndrome
1984
Hierarchical design of pseudosymmetric protein nanocages
2024 StandoutNatureNobel
Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
2016
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34 + Hematopoietic Stem and Progenitor Cells
2017
Age-related mutations associated with clonal hematopoietic expansion and malignancies
2014
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
2008
Inflammation and cancer
2002 StandoutNature
Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS‐T) a necessary or useful diagnostic category?
2008
A view on drug resistance in cancer
2019 StandoutNature
Are myelodysplastic syndromes “cancer”?
2006
Cell production rates in human tissues and tumours and their significance. Part II: clinical data
2000
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
2016 Nature
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease
2008
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference
2007
Analysis of genes and chromosomes by nonisotopic in situ hybridization
1991
Comprehensive Molecular Structure of the Eukaryotic Ribosome
2009 StandoutNobel
Chronic myelomonocytic leukemia
2002
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Ribosomal Protein Mutations Induce Autophagy through S6 Kinase Inhibition of the Insulin Pathway
2014
Cell death and proliferation in acute slices and organotypic cultures of mammalian CNS
2009
The changing landscape of atherosclerosis
2021 StandoutNature
Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: A retrospective study of 322 bone marrows
2009
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
2017 Nature
The Oncogenic Cysteine-rich LIM domain protein Rbtn2 is essential for erythroid development
1994 StandoutNobel
Drosophila Ribosomal Protein Mutants Control Tissue Growth Non-Autonomously via Effects on the Prothoracic Gland and Ecdysone
2011
A germline mutation of the KIF1Bβ gene on 1p36 in a family with neural and nonneural tumors
2008
Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer
2013
Apoptotic mechanisms in the control of erythropoiesis
2004
JmjC-domain-containing proteins and histone demethylation
2006
Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice
2006 StandoutNature
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
2012
The biology of the P-glycoproteins
1995
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
2012 Standout
Turnover of resident microglia in the normal adult mouse brain
1992
Intrinsic Immunity Shapes Viral Resistance of Stem Cells
2017 StandoutNobel
A Ribosomopathy Reveals Decoding Defective Ribosomes Driving Human Dysmorphism
2017 StandoutNobel
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
2015
IDH mutation impairs histone demethylation and results in a block to cell differentiation
2012 Nature
Chromosomal Abnormalities in Cancer
2008
Chronic immune activation and inflammation in the pathogenesis of aids and cancer
2002
Genetic instability in colorectal cancers
1997 StandoutNature
Bromodeoxyuridine immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically defined population
1989
Specific metaphase and interphase detection of the breakpoint region in 8q24 of burkitt lymphoma cells by triple‐color fluorescence in situ hybridization
1992
Acquired mutations in TET2 are common in myelodysplastic syndromes
2009
Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease
2012
Principles and Strategies for Developing Network Models in Cancer
2011
Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
2009
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
2013
Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML
2012
DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis
2020 StandoutNatureNobel
Bone metastasis: the importance of the neighbourhood
2016
Selective Inhibitors of Glutathione Transferase P1 with Trioxane Structure as Anticancer Agents
2015
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission.
1989 StandoutNobel
Synapse-independent and synapse-dependent apoptosis of cerebellar granule cells in postnatal rabbits occur at two subsequent but partly overlapping developmental stages
2002
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
2014
A Controlled Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients after Treatment for Acute Myelogenous Leukemia
1995
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase
2007 StandoutNobel
Cancer-related inflammation
2008 StandoutNature
The inflammatory reflex
2002 StandoutNature
lincRNAs act in the circuitry controlling pluripotency and differentiation
2011 StandoutNature
Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics
2015
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
2015
The SF3b complex: splicing and beyond
2020
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
2014
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
2017 StandoutNature
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
1994
HMGB1 as a Late Mediator of Lethal Systemic Inflammation
2001
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase
2018 StandoutNobel
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification
2009
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
2009
Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology
2006
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
2014
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
Bone marrow transplantation performed as first-time treatment in two cases of secondary acute myeloid leukemia
1984
Recent developments in myelodysplastic syndromes
2014
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms
2012
ASXL1 mutations are frequent and prognostically detrimental in CSF3R‐mutated chronic neutrophilic leukemia
2015
Identification and transcriptome analysis of erythroblastic island macrophages
2019 StandoutNobel
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Allogeneic Marrow Transplantation in the Treatment of Preleukemia
1984
Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein.
1993
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
2016
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
2007
Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts
2012
Long-Distance Neuronal Migration in the Adult Mammalian Brain
1994 StandoutScience
Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes
2014
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance
2015
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
2013
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
1997
Role of Glutathione in Cancer Progression and Chemoresistance
2013
Trajectories of the ribosome as a Brownian nanomachine
2014 StandoutNobel
Modular repeat protein sculpting using rigid helical junctions
2020 StandoutNobel
Treatment of the Newly Diagnosed Adult with De Noyo Acute Myeloid Leukemia
1993
Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview
2019
Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine
1988
Cancer Genome Landscapes
2013 StandoutScience
Ribosomopathies: human disorders of ribosome dysfunction
2010
A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels
1998 StandoutNobel
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations
2014
Sudestada1, a Drosophila ribosomal prolyl-hydroxylase required for mRNA translation, cell homeostasis, and organ growth
2014 StandoutNobel
Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
1986
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
2014
Current status of cytogenetic research in childhood acute lymphoblastic leukemia
1993
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Does a Diagnosis of Myelogenous Leukemia Require 20% Marrow Myeloblasts, and Does <5% Marrow Myeloblasts Represent a Remission? The History and Ambiguity of Arbitrary Diagnostic Boundaries in the Understanding of Myelodysplasia
2013
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
2018
Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease.
1987 StandoutNobel
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
2013 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Treatment of Therapy-Related Leukemia and Myelodysplastic Syndrome
1993
Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia
2014
Accurate proteome-wide missense variant effect prediction with AlphaMissense
2023 StandoutScienceNobel
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
1996
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
1993
Functional dichotomy of ribosomal proteins during the synthesis of mammalian 40S ribosomal subunits
2010
Works of Azra Raza being referenced
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
2012
Chronic Myelomonocytic Leukemia Evolving From Preexisting Myelodysplasia Shares Many Features With De Novo Disease
2006
Chronic Myelomonocytic Leukemia Evolving From Preexisting Myelodysplasia Shares Many Features With De Novo Disease
2006
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
2012
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)
2011
Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1
2019
Consilience across evolving dysplasias affecting myeloid, cervical, esophageal, gastric and liver cells: common themes and emerging patterns
2000
An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
2008
Myelodysplastic syndromes
2007
Simultaneous immunohistochemical detection of IUdR and BrdU infused intravenously to cancer patients.
1991
MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia
1990
The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
2012
Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis
1995
Decitabine improves patient outcomes in myelodysplastic syndromes
2006
In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdU in patients with hematopoietic malignancies
1992
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
2006
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31
2001
Excessive Proliferation Matched by Excessive Apoptosis in Myelodysplastic Syndromes: The Cause-Effect Relationship
1997
Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes
2000
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts
2014 Nature
Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification
2008
Detection of monosomy 7 in interphase cells of patients with myeloid disorders
1990
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome
2011
Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation
2016
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
2008 Nature
In vivo determinations of labelling index of metastatic colorectal carcinoma and normal colonic mucosa using intravenous infusions of bromodeoxyuridine
1988
In vivo determination of cell cycle kinetics of non-Hodgkin's lymphomas using iododeoxyuridine and bromodeoxyuridine.
1992
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
2001
Isolation and functional characterization of human erythroblasts at distinct stages: implications for understanding of normal and disordered erythropoiesis in vivo
2013
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
2014
Double labeling and in vitro versus in vivo incorporation of bromodeoxyuridine in patients with acute nonlymphocytic leukemia
1985
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
2007
Identification of Dido1 Mutation Associated with Familial Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML)
2012
Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the multicenter MDS-003 Study
2005
Coordinate Loss of a MicroRNA Mir 145 and a Protein-Coding Gene RPS14 Cooperate in the Pathogenesis of 5q- Syndrome.
2009
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
2007
Remicade as TNF Suppressor in Patients with Myelodysplastic Syndromes
2004
Therapy of Secondary Acute Nonlymphocytic Leukemia with Cytarabine
1983
High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study
1986
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.
1987
Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
2009
Utility and sensitivity of anti BrdU antibodies in assessing S‐phase cells compared to autoradiography
1985
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q− syndrome
2011
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
2013
Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes [see comments]
1995
The treatment of acute myelocytic leukemia in patients 30 years of age and younger
1982
Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
2008
Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.
2006